Memphis Extends Talkspace Partnership, Expands Mental Health Services to Dependents 13+ Talkspace (NASDAQ: TALK), a leading online behavioral healthcare company, announced it will continue supporting the City of Memphis for a fifth consecutive year by providing free virtual therapy and…
Scale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies Scale Biosciences (Scale Bio™), a leader in scalable single cell analysis, has announced the launch of its QuantumScale Single Cell RNA kits. These next-generation products are designed to…
Median Technologies to Present eyonis™ LCS AI Software for Lung Cancer Screening at ECR Median Technologies, a leader in artificial intelligence (AI)-powered software for early cancer diagnostics, has announced its participation in the 2025 European Congress of Radiology (ECR) in…
Healx Doses First Patient in Phase 2 Trial of HLX-1502 for Neurofibromatosis Type 1 Healx, a clinical-stage biotech company utilizing AI to advance treatments for rare diseases, has announced that the first patient has been dosed in its Phase 2…
PepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapies, recently announced promising early results from the ongoing FREEDOM-DM1 Phase 1 trial. The trial is investigating…
Seraph 100 May Reduce Tumor Particles in Blood Samples from Pancreatic Cancer Patients A recent laboratory study has explored the potential therapeutic benefits of blood purification for patients with metastatic pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and…
Bruker Enhances Single-Cell Proteomics and Immunopeptidomics with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) unveiled significant advancements in 4D-Proteomics™ performance, along with new software and applications aimed at providing deeper biological…
FDA Accepts Bristol Myers Squibb’s Application for Opdivo® + Yervoy® in MSI-High or MMR-Deficient Cancer Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) for Opdivo®…
Summit Therapeutics Reports Q4 and 2024 Full-Year Financial and Operational Results Summit Therapeutics Inc. (NASDAQ: SMMT) has provided an update on its operational progress and financial results for the fourth quarter and full year ending December 31, 2024. The company…
Almirall 2024 Results: Surpasses Guidance, Poised for Sustained Growth Almirall, S.A., a global biopharmaceutical company based in Barcelona, has reported strong financial results for the full year of 2024. The company saw a notable increase in total revenue, achieving €990.6…